Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of ANX776 (DARC) in Glaucoma and NAION
NCT02394613Phase 1Unknown
- Sponsor
- University College London
- Start
- May 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ANX776 in Glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) (4 cohorts), sponsored by University College London. Primary endpoint: Number and nature of adverse events at 24 hours. Status: unknown.
02
Drugs
ANX776
03
Conditions
Glaucomanon-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT02394613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394613.